Adlai Nortye

Adlai Nortye is a global clinical-stage biotechnology company focused on innovative oncology drugs, with its R&D and global clinical operation centers in the US and China. The Company has built a global pipeline through collaborations and internal discovery with six drug candidates in pipeline. Currently, three of them are in clinical stage include (i) Buparlisib (AN2025), a pan-PI3K inhibitor in a global Phase III clinical trial, (ii) Palupiprant (AN0025), an oral EP4 antagonist is undergoing Phase 1b trial in combination with pembrolizumab in patients with multiple solid tumors; and (iii) AN4005, an oral small molecule PD-L1 drug which is currently in Phase I trial. In addition, a Phase I clinical trial has been initiated for a combination therapy consisting of AN2025, AN0025, and atezolizumab targeting a variety of PIK3CA mutant solid tumors. We also continue to advance three in-house preclinical programs include: AN8025, a multifunctional antibody as T cell and antigen-presenting cell (“APC”) modulator fusion protein; AN1025, an oral small molecule degrader of β-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.